- Trials with a EudraCT protocol (61)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
61 result(s) found for: Observational studies.
Displaying page 1 of 4.
EudraCT Number: 2014-004827-29 | Sponsor Protocol Number: VX14-661-110 | Start Date*: 2015-09-01 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Open-label, Rollover Study to Evaluate the Safety and Efficacy of Long term Treatment With VX 661 in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, ... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) IE (Completed) GB (GB - no longer in EU/EEA) BE (Completed) SE (Completed) AT (Completed) FR (Completed) DK (Completed) NL (Completed) DE (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000842-16 | Sponsor Protocol Number: PIRVACoV | Start Date*: 2021-03-18 | ||||||||||||||||
Sponsor Name:Kristina Jakobsson | ||||||||||||||||||
Full Title: Does PFAS-exposure modify the risk of COVID-19 infection or the immunological response after vaccination against SARS-CoV-2? | ||||||||||||||||||
Medical condition: An observational study in healthy, differently PFAS-exposed subjects to check if PFAS modifies the immunological response to SARS-CoV-2 vaccination. The immunological response is quantified as SARS... | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: SE (Completed) | ||||||||||||||||||
Trial results: (No results available) |
EudraCT Number: 2012-005636-29 | Sponsor Protocol Number: IDX-03YF | Start Date*: 2013-05-17 |
Sponsor Name:Idenix Pharmaceuticals, Inc. | ||
Full Title: 3-Year, Observational Study to Evaluate the Durability of Sustained Viral Response and the Kinetics of Antiviral-Resistant HCV in Subjects Who Participated in Studies of Idenix Anti-HCV, Direct Act... | ||
Medical condition: Chronic Hepatitis C Infection | ||
Disease: | ||
Population Age: Adults | Gender: Male, Female | |
Trial protocol: BG (Prematurely Ended) | ||
Trial results: View results |
EudraCT Number: 2019-001074-29 | Sponsor Protocol Number: CLOU064A2201E1 | Start Date*: 2019-10-10 | |||||||||||
Sponsor Name:Novartis Pharma AG | |||||||||||||
Full Title: An open-label, multicenter, extension study to evaluate the long-term safety and tolerability of LOU064 in eligible subjects with CSU who have participated in CLOU064A2201 | |||||||||||||
Medical condition: Chronic Spontaneous Urticaria | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) HU (Completed) CZ (Completed) SK (Completed) FR (Completed) DK (Completed) ES (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-001644-11 | Sponsor Protocol Number: VX15-809-110 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 6 Years and Older With Cystic Fibrosis, Homozy... | |||||||||||||
Medical condition: Cystic Fibrosis | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: SE (Ongoing) GB (Completed) BE (Completed) DK (Completed) DE (Completed) FR (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-002945-36 | Sponsor Protocol Number: TRA108132 | Start Date*: 2007-03-12 | |||||||||||
Sponsor Name:GlaxoSmithKline Research and Development Ltd | |||||||||||||
Full Title: LENS – Long-term Eltrombopag ObservatioNal Study - A long term observational ocular safety study in adults who have received study medication (SB-497115-GR / eltrombopag olamine or placebo) in a ph... | |||||||||||||
Medical condition: Long-term ocular safety specifically related to cataract formation in subjects who have previously participated in a phase II or III protocol for eltrombopag (SB-497715-GR) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) SE (Completed) ES (Completed) CZ (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2008-005667-34 | Sponsor Protocol Number: G0701625 | Start Date*: 2009-01-16 | |||||||||||
Sponsor Name:University of Edinburgh [...] | |||||||||||||
Full Title: Randomised Trial of Genetic Testing and Targeted Zoledronic acid therapy to Prevent SQSTM1 Mediated Paget's Disease (Zoledronate in the Prevention of Paget's). | |||||||||||||
Medical condition: Paget's disease of the bone (PDB) | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) BE (Completed) IT (Completed) IE (Completed) ES (Ongoing) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-003303-38 | Sponsor Protocol Number: EPI40670/WWE115682 | Start Date*: 2011-10-13 | |||||||||||
Sponsor Name:ViiV Healthcare UK Limited | |||||||||||||
Full Title: Observational Drug Exposure Registry for Long-Term Follow-Up of Subjects Exposed to GSK2248761 | |||||||||||||
Medical condition: HIV-1 infected adults | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2021-000630-34 | Sponsor Protocol Number: MLN0002-3029 | Start Date*: 2022-12-09 |
Sponsor Name:Takeda Development Center Americas, Inc. | ||
Full Title: A Phase 3b Extension Study to Evaluate the Long-term Safety of Vedolizumab Intravenous in Pediatric Patients With Ulcerative Colitis or Crohn’s Disease | ||
Medical condition: Active Ulcerative Colitis (UC) or Crohn's disease (CD) | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: HU (Trial now transitioned) PL (Trial now transitioned) CZ (Prematurely Ended) ES (Prematurely Ended) SK (Prematurely Ended) GR (Trial now transitioned) BE (Trial now transitioned) LT (Completed) HR (Trial now transitioned) Outside EU/EEA | ||
Trial results: (No results available) |
EudraCT Number: 2014-001369-28 | Sponsor Protocol Number: 880 | Start Date*: 2014-10-30 | |||||||||||
Sponsor Name:Gateshead Health NHS Foundation Trust | |||||||||||||
Full Title: THYRoxine in Acute Myocardial Infarction (ThyrAMI) | |||||||||||||
Medical condition: Hypothyroidism and Acute Myocardial Infarction | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2012-003581-40 | Sponsor Protocol Number: CRO1992 | Start Date*: 2012-09-28 | |||||||||||
Sponsor Name:Imperial College, Research Governance Manager | |||||||||||||
Full Title: A prospective, observational study to examine the effects of ageing on the clinical outcomes of people living with HIV in England and Ireland. | |||||||||||||
Medical condition: HIV | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) IE (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-000604-41 | Sponsor Protocol Number: VX12-809-105 | Start Date*: 2014-01-21 | |||||||||||
Sponsor Name:Vertex Pharmaceuticals Incorporated | |||||||||||||
Full Title: A Phase 3, Rollover Study to Evaluate the Safety and Efficacy of Long-term Treatment With Lumacaftor in Combination With Ivacaftor in Subjects Aged 12 Years and Older With Cystic Fibrosis, Homozygo... | |||||||||||||
Medical condition: Cystic fibrosis in patients homozygous or heterozygous for the F508del-CFTR Mutation | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: IT (Completed) CZ (Completed) SE (Completed) AT (Completed) BE (Completed) GB (Completed) DE (Completed) NL (Completed) ES (Completed) IE (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2013-002549-12 | Sponsor Protocol Number: A4091064 | Start Date*: 2015-09-08 | ||||||||||||||||
Sponsor Name:Pfizer Inc, 235 East 42nd Street, New York, NY 10017 | ||||||||||||||||||
Full Title: A PHASE 3, MULTICENTER, LONG-TERM OBSERVATIONAL STUDY OF SUBJECTS FROM TANEZUMAB STUDIES WHO UNDERGO A TOTAL KNEE, HIP OR SHOULDER REPLACEMENT | ||||||||||||||||||
Medical condition: Osteoarthritis of the hip or knee | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||
Trial protocol: HU (Completed) AT (Completed) ES (Completed) BG (Completed) DE (Completed) PT (Completed) FI (Completed) GB (Completed) SE (Completed) LT (Completed) HR (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2019-004753-87 | Sponsor Protocol Number: BBI608-901 | Start Date*: 2020-03-18 |
Sponsor Name:Sumitomo Dainippon Pharma Oncology, Inc. | ||
Full Title: A Rollover Study to Provide Continued Access to Napabucasin for Patients Enrolled in Sumitomo Dainippon Pharma Oncology, Inc. sponsored Napabucasin Protocols | ||
Medical condition: Metastatic Pancreatic Adenocarcinoma and Metastatic Colorectal Cancer. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: FR (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2011-000903-41 | Sponsor Protocol Number: A3921053 | Start Date*: 2011-10-24 | |||||||||||
Sponsor Name:Pfizer, S.L.U. | |||||||||||||
Full Title: AN OBSERVATIONAL STUDY TO COLLECT FOLLOW-UP CLINICAL DATA FROM KIDNEY TRANSPLANT RECIPIENTS WHO RECEIVED TOFACITINIB (CP-690,550) IN COMPLETED PHASE 2 STUDIES | |||||||||||||
Medical condition: KIDNEY TRANSPLANT | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) BE (Completed) CZ (Completed) DE (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2015-003028-30 | Sponsor Protocol Number: 808040019 | Start Date*: 2015-11-02 |
Sponsor Name:Technische Universität München, Fakultät für Medizin | ||
Full Title: Fr1da Insulin Intervention - Mechanistic study using oral insulin for immune and treatment efficacy in secondary prevention of type 1 diabetes | ||
Medical condition: Risk for type 1 diabetes | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: (No results available) |
EudraCT Number: 2014-004674-42 | Sponsor Protocol Number: GS-US-334-1113 | Start Date*: 2015-11-20 | ||||||||||||||||
Sponsor Name:Gilead Sciences, Inc. | ||||||||||||||||||
Full Title: A Long Term Follow-up Registry for Adolescent and Pediatric Subjects Who Received a Gilead Hepatitis C Virus Direct Acting Antiviral (DAA) in Gilead-Sponsored Chronic Hepatitis C Infection Trials | ||||||||||||||||||
Medical condition: Chronic Hepatitis C virus infection | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Children, Adolescents, Under 18, Adults | Gender: Male, Female | |||||||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) DE (Completed) BE (Completed) PL (Completed) IT (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2010-019102-17 | Sponsor Protocol Number: Y-55-52120-147 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Ipsen Pharma SAS | |||||||||||||
Full Title: A PHASE III, PROSPECTIVE, MULTICENTRE, OPEN LABEL, EXTENSION STUDY ASSESSING THE LONG TERM SAFETY AND EFFICACY OF REPEATED TREATMENT WITH DYSPORT USED IN THE TREATMENT OF LOWER LIMB SPASTICITY IN C... | |||||||||||||
Medical condition: Lower limb spasticity in children with dynamic equinus foot deformity due to cerebral palsy | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: FR (Completed) PL (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2006-006373-25 | Sponsor Protocol Number: A3921029 | Start Date*: 2007-03-23 | |||||||||||
Sponsor Name:Pfizer, S.A. | |||||||||||||
Full Title: ESTUDIO OBSERVACIONAL PROSPECTIVO PARA EVALUAR LA SEGURIDAD A LARGO PLAZO Y EL ESTADO FUNCIONAL DE SUJETOS CON ARTRITIS REUMATOIDE INCLUIDOS PREVIAMENTE EN ESTUDIOS DE CP-690,550 A PROSPECTIVE OBS... | |||||||||||||
Medical condition: CP-690,550 se está desarrollando como fármaco antirreumático modificador de la enfermedad (FARME) para el tratamiento de la artritis reumatoide (AR). CP 690,550 is being developed as a disease mo... | |||||||||||||
|
|||||||||||||
Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
Trial protocol: ES (Completed) AT (Completed) SE (Completed) SK (Completed) CZ (Completed) GR (Completed) DE (Completed) FI (Completed) BG (Completed) GB (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2007-002243-25 | Sponsor Protocol Number: CAAE581A2203E2 | Start Date*: 2007-08-28 |
Sponsor Name:Novartis Pharma Services AG | ||
Full Title: An observational, safety follow-up extension to studies 2203 and 2203E1 to assess the safety of AAE581 in postmenopausal women with osteopenia/osteoporosis | ||
Medical condition: Osteoporosis | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Female | |
Trial protocol: PL (Completed) FR (Completed) AT (Completed) ES (Completed) CZ (Completed) SK (Completed) | ||
Trial results: View results |
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here

Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
